The Current Ratio as of December 2024 (TTM) for Innovent Biologics, Inc. (IVBXF) is 3.00

According to Innovent Biologics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.00. This represents a change of 100.00% compared to the average of 1.50 of the last 4 quarters.

Innovent Biologics, Inc. (IVBXF) Historical Current Ratio (quarterly & annually)

How has IVBXF Current Ratio performed in the past?

The mean historical Current Ratio of Innovent Biologics, Inc. over the last ten years is 7.76. The current 3.00 Current Ratio has changed 3.77% with respect to the historical average. Over the past ten years (40 quarters), IVBXF's Current Ratio was at its highest in in the September 2017 quarter at 8.85. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Innovent Biologics, Inc. (IVBXF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Innovent Biologics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innovent Biologics, Inc. (IVBXF) Average Current Ratio

How has IVBXF Current Ratio performed in the past?

The current Current Ratio of Innovent Biologics, Inc. (IVBXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Innovent Biologics, Inc. (IVBXF) Current Ratio vs. Peers

How is IVBXF’s Current Ratio compared to its peers?

Innovent Biologics, Inc.’s Current Ratio is greater than Telix Pharmaceuticals Limited (0.99), less than Keros Therapeutics, Inc. (19.03), greater than MAIA Biotechnology, Inc. (2.56), less than Graphite Bio, Inc. (11.47), less than Genscript Biotech Corporation (0), less than Oxford Nanopore Technologies plc (4.15), less than Nuvalent, Inc. (4.45), less than Crinetics Pharmaceuticals, Inc. (23.07), less than Inhibrx Biosciences, Inc. (16.38), less than Merus N.V. (4.70), less than Lyell Immunopharma, Inc. (8.32), less than Kronos Bio, Inc. (13.43), less than Theseus Pharmaceuticals, Inc. (8.32), less than Cullinan Oncology, Inc. (29.93), less than Mersana Therapeutics, Inc. (24.46), greater than Relay Therapeutics, Inc. (2.35), less than Arcus Biosciences, Inc. (18.42), less than null (5.24),

Build a custom stock screener for Innovent Biologics, Inc. (IVBXF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innovent Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innovent Biologics, Inc. (IVBXF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innovent Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.